Cambridge Investment Research Advisors Inc. Cuts Stock Position in DexCom, Inc. (NASDAQ:DXCM)

Cambridge Investment Research Advisors Inc. lessened its holdings in DexCom, Inc. (NASDAQ:DXCM) by 24.5% in the first quarter, according to its most recent filing with the SEC. The institutional investor owned 51,265 shares of the medical device company’s stock after selling 16,667 shares during the period. Cambridge Investment Research Advisors Inc.’s holdings in DexCom were worth $7,110,000 as of its most recent SEC filing.

A number of other institutional investors have also bought and sold shares of the business. Capital World Investors boosted its holdings in shares of DexCom by 130.7% during the 4th quarter. Capital World Investors now owns 9,278,685 shares of the medical device company’s stock valued at $1,151,392,000 after purchasing an additional 5,256,092 shares during the last quarter. Norges Bank bought a new position in shares of DexCom during the 4th quarter valued at about $540,178,000. Artisan Partners Limited Partnership boosted its holdings in shares of DexCom by 164.8% during the 4th quarter. Artisan Partners Limited Partnership now owns 5,900,308 shares of the medical device company’s stock valued at $732,169,000 after purchasing an additional 3,672,471 shares during the last quarter. Capital Research Global Investors boosted its holdings in shares of DexCom by 21.4% during the 4th quarter. Capital Research Global Investors now owns 15,296,032 shares of the medical device company’s stock valued at $1,898,085,000 after purchasing an additional 2,695,296 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA bought a new position in shares of DexCom during the 4th quarter valued at about $231,773,000. Hedge funds and other institutional investors own 97.75% of the company’s stock.

DexCom Trading Up 0.4 %

Shares of NASDAQ DXCM traded up $0.49 during trading hours on Friday, reaching $115.79. The stock had a trading volume of 3,009,534 shares, compared to its average volume of 2,637,164. DexCom, Inc. has a 52-week low of $74.75 and a 52-week high of $142.00. The firm has a market cap of $46.05 billion, a price-to-earnings ratio of 74.70, a P/E/G ratio of 2.83 and a beta of 1.22. The business’s fifty day moving average price is $129.67 and its two-hundred day moving average price is $125.88. The company has a current ratio of 2.90, a quick ratio of 2.53 and a debt-to-equity ratio of 1.08.

DexCom (NASDAQ:DXCM) last issued its earnings results on Thursday, April 25th. The medical device company reported $0.32 earnings per share for the quarter, topping the consensus estimate of $0.27 by $0.05. The business had revenue of $921.00 million during the quarter, compared to analysts’ expectations of $911.20 million. DexCom had a return on equity of 31.01% and a net margin of 16.82%. Analysts expect that DexCom, Inc. will post 1.78 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, EVP Michael Jon Brown sold 652 shares of DexCom stock in a transaction that occurred on Friday, May 31st. The shares were sold at an average price of $119.24, for a total transaction of $77,744.48. Following the transaction, the executive vice president now directly owns 67,560 shares of the company’s stock, valued at $8,055,854.40. The sale was disclosed in a filing with the SEC, which is accessible through this link. In related news, EVP Michael Jon Brown sold 652 shares of the firm’s stock in a transaction dated Friday, May 31st. The stock was sold at an average price of $119.24, for a total transaction of $77,744.48. Following the sale, the executive vice president now owns 67,560 shares of the company’s stock, valued at $8,055,854.40. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Sadie Stern sold 20,321 shares of the business’s stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $133.61, for a total transaction of $2,715,088.81. Following the completion of the transaction, the executive vice president now owns 80,441 shares of the company’s stock, valued at $10,747,722.01. The disclosure for this sale can be found here. Insiders have sold a total of 187,293 shares of company stock worth $25,295,452 in the last three months. Corporate insiders own 0.30% of the company’s stock.

Wall Street Analyst Weigh In

DXCM has been the subject of a number of analyst reports. Citigroup increased their price target on shares of DexCom from $148.00 to $161.00 and gave the company a “buy” rating in a report on Wednesday, April 3rd. StockNews.com raised shares of DexCom from a “hold” rating to a “buy” rating in a report on Sunday, June 2nd. Canaccord Genuity Group increased their price target on shares of DexCom from $144.00 to $145.00 and gave the company a “buy” rating in a report on Friday, April 26th. Raymond James increased their price target on shares of DexCom from $151.00 to $160.00 and gave the company a “strong-buy” rating in a report on Friday, April 26th. Finally, Redburn Atlantic initiated coverage on shares of DexCom in a report on Thursday, May 30th. They issued a “neutral” rating and a $130.00 price target for the company. Three investment analysts have rated the stock with a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, DexCom has an average rating of “Moderate Buy” and a consensus target price of $140.94.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.